Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Circ Heart Fail. 2014 Oct 22;8(1):89–97. doi: 10.1161/CIRCHEARTFAILURE.114.001174

Figure 3. ProBNP1-108 processing and degradation based on %EF and high proBNP1-108 concentration.

Figure 3

A and B: Sub-analysis of ex vivo ProBNP1-108 processing and degradation in HF by %EF. Densitometric analysis of unprocessed proBNP1-108 (A) and processed form (BNP1-32/3-32) (B) at indicated times; EF<50% (closed square), EF≥50% (grayed circle), or normals (opened circle with breaking line). Values are mean ± SEM. p values were shown in graphs analyzed by 2-way ANOVA with Bonferroni multiple comparison test. No significant difference between groups at indicated times, 2-way ANOVA with Bonferroni multiple comparison test. C and D: Ex vivo ProBNP1-108 processing and degradation in normals with or without pretreatment with proBNP1-108. Representative WB for His-tag proBNP1-108 incubated in serum samples from normal subjects (n=4) for indicated times. Samples were pretreated with or without 500 pg/ml non-glycosylated proBNP1-108 (C) or glycosylated proBNP1-108 (D) before treatment with His-tag proBNP1-108.